Advertisement
Business
Subscribe to Business

The Lead

Judge to Hear Objections to Hopkins Settlement

September 19, 2014 8:25 am | by JULIET LINDERMAN, Associated Press | News | Comments

A Baltimore judge was set to hear objections Friday to a preliminary $190 million dollar settlement between Johns Hopkins Hospital System and more than 8,000 patients of a gynecologist who used tiny cameras to secretly photograph women and girls during examinations.

PCI Acquires Biotec Services

September 19, 2014 8:21 am | News | Comments

The addition significantly expands PCI's presence in the UK/EU to support global investigational...

Soligenix Awarded $24.7M NIAID Contract to Develop Heat Stable RiVax Vaccine

September 19, 2014 8:11 am | News | Comments

The objectives of the contract are to advance the development of Soligenix's thermostabilization...

China Fines GSK $492M for Bribery

September 19, 2014 5:47 am | by Joe Mcdonald - AP Business Writer - Associated Press | News | Comments

A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been...

View Sample

FREE Email Newsletter

Merck KGaA Strengthens Executive Board

September 18, 2014 2:20 pm | News | Comments

Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belén Garijo was appointed to the Executive Board to take over leadership for the Pharma business.

Elanco Animal Health, Dow AgroSciences Announce Strategic R&D Agreement

September 18, 2014 9:09 am | News | Comments

Elanco, the animal health division of Eli Lilly and Company, and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, are announcing a strategic R&D agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.

Bayer to Split Off Polymer Division with IPO

September 18, 2014 7:45 am | by The Associated Press | News | Comments

German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The Leverkusen-based company that invented aspirin said Thursday the move would be part of an effort to focus the group on its health care and crop science businesses.

Advertisement

Sun Pharma and Merck Announce $80M Licensing Agreement for Tildrakizumab

September 17, 2014 9:00 am | News | Comments

Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.

Auxilium Pharma Board Adopts Anti-Takeover Plan

September 17, 2014 8:48 am | by The Associated Press | News | Comments

The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.   

Doctor Pleads Guilty to Cancer Treatment Fraud

September 17, 2014 8:31 am | by ED WHITE, Associated Press | News | Comments

A Detroit-area cancer doctor accused of putting people through unnecessary treatments and then billing insurers for millions of dollars pleaded guilty to fraud Tuesday, admitting that he knew his patients often didn't need chemotherapy.   

EMD Serono and Sutro Biopharma Announce $298M Deal to Develop Antibody Drug Conjugates

September 17, 2014 8:14 am | News | Comments

EMD Serono and Sutro Biopharma announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.

Endo Makes $1.4B Offer for Auxilium Pharma

September 16, 2014 5:45 pm | by The Associated Press | News | Comments

Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.

Advertisement

Big Cities Take Aim at Prescription Painkillers

September 16, 2014 2:25 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.      

MedGenesis Enters Into Agreement with Pfizer for Potential Treatments for Parkinson's Disease

September 16, 2014 9:07 am | News | Comments

MedGenesis Therapeutix has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.

Mylan Commences Clinical Trials for Generic Versions of Advair Diskus and Insulin Analog to Lantus

September 16, 2014 8:59 am | News | Comments

Mylan today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus. In October 2014, Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.

The Future of Chemicals: Managing Complexity and Enabling Growth with Natural Supply Chains

September 16, 2014 8:45 am | by Rohit Singh, Principal, Strategy; and Marc Waco, Partner, PwC US Chemicals Advisory Leader | Blogs | Comments

In an increasingly complex and challenging climate, chemical companies are facing a combination of shifting market forces and an increasingly heterogeneous customer set. Many organizations are focusing solely on all-out growth or across-the-board cost-cutting strategies in an attempt to adjust course.

AstraZeneca and Lilly to Develop and Commercialize Alzheimer’s Disease Treatment

September 16, 2014 8:39 am | News | Comments

AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.  

Advertisement

Allergan Agrees to Move Forward with Meeting

September 16, 2014 6:44 am | by The Associated Press | News | Comments

Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.

NY Files Alzheimer's Drug Lawsuit

September 15, 2014 7:42 pm | by Michael Virtanen - Associated Press - Associated Press | News | Comments

New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses from cheaper generic alternatives coming out next year.

Avanir Pharma Soars on Agitation Drug Study

September 15, 2014 3:46 pm | by The Associated Press | News | Comments

Shares of Avanir Pharmaceuticals soared Monday after the company reported positive clinical trial results for a drug that is designed to treat agitation in Alzheimer's disease patients. The company said patients who were treated with AVP-923 were less agitated than patients given a placebo.

Skin Shocks Used at Massachusetts School Draw FDA Scrutiny

September 15, 2014 8:44 am | by JENNIFER C. KERR, Associated Press; LAURAN NEERGAARD, Associated Press | News | Comments

The Food and Drug Administration is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use skin shocks as aversive conditioning for aggressive patients.

U.S. Government, WHO Seek Ways to Expand Production of Ebola Drugs, Vaccines

September 15, 2014 8:20 am | by Helen Branswell, The Canadian Press | News | Comments

High level efforts are underway to find ways to substantially ramp up production of experimental Ebola vaccines and drugs, officials at the World Health Organization and within the U.S. government say.         

FDA Accepts Tuzistra XR NDA for Full Review

September 15, 2014 8:12 am | News | Comments

Vernalis and Tris Pharma announced that the FDA has confirmed that the New Drug Application for Tuzistra XR has been accepted for full review. This triggers a milestone payment from Vernalis to Tris.        

Gilead to License Generic Version of Sovaldi

September 15, 2014 8:07 am | by The Associated Press | News | Comments

Gilead Sciences says it has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.           

Chemical Industry Tries to Shape Regulations

September 12, 2014 3:31 pm | by FREDERIC J. FROMMER, Associated Press | News | Comments

The powerful chemical industry is putting its lobbying muscle behind legislation that would establish standards for chemicals used in products from household goods to cellphones and plastic water bottles — but also make it tougher for states to enact their own regulations.

Feds Say Bayer Colon Supplement Makes Bogus Claims

September 12, 2014 3:23 pm | News | Comments

The Department of Justice filed a court motion against the German conglomerate over its advertisements for Phillips' Colon Health, which claims to prevent diarrhea, constipation, gas and bloating. Federal officials say the company does not have reliable scientific evidence to support those claims.

Livestrong Takes Hit after Armstrong Confession

September 12, 2014 8:19 am | by JIM VERTUNO, Associated Press | News | Comments

The Livestrong cancer charity is reporting a sharp drop in donations and revenue after founder Lance Armstrong admitted taking performance-enhancing drugs during most of his record-setting cycling career.        

Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus

September 12, 2014 8:09 am | News | Comments

The University of Pennsylvania today reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial

September 12, 2014 8:01 am | News | Comments

Oxygen Biotherapeutics has elected to stop the current Phase IIb trial for its Oxycyte drug candidate and consider strategic alternatives for the program moving forward. The company will review the data generated on the patients enrolled in the trial to date.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading